



Possible Biomarkers in Oral Tumors and Their Clinical Significance

Guest Editor:

Prof. Dr. Daisuke Uchida

Department of Oral and
Maxillofacial Surgery, Ehime
University Graduate School of
Medicine, 454 Shitsukawa, Toon
791-0295, Ehime, Japan

Deadline for manuscript
submissions:

30 November 2024

Message from the Guest Editor

Oral tumors are generally easy to access by visual inspection and palpation, and most definitive diagnoses are determined by the histopathological examination after biopsies. However, the diagnosis may often be difficult due to their histopathological varieties, especially in tumors originated from tooth germ, minor salivary gland, and mesenchyme, and so on.

On the other hand, squamous cell carcinoma (SCC) is a typical malignancy in the oral cavity, the definitive diagnosis is comparatively easy because of their accessibility and characteristic histology. Although oral SCC is generally treated with surgery, radiotherapy, chemotherapy, immunotherapy, or their combination, the prognosis and the prediction of therapeutic effect are mainly determined by the histopathological degree of invasion and differentiation. Concerning the biomarker for oral SCC, serum SCC antigen is clinically applied but is not reliable as a sensitive biomarker.

In this special issue, researchers who are a head and neck oncologist and has a wealth of basic data will discuss biomarkers that are expected to be applied clinically in relation to the diagnosis, recurrence, metastasis, or prognosis of oral tumors.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)